Consulting for effective life science
R&D and partnering
Haberman Associates is a Boston-based
consulting firm, founded in 1993, that specializes in science
and technology strategy for life science companies.
We assist your company to achieve its
business goals in new product development and commercialization.
Our focus is on effective R&D, business development,
and partnering.
Clients have used our consulting services
to help them:
- discover and develop new drugs, diagnostics, and research
products
- improve their drug pipelines
- identify and evaluate potential partners
- develop new applications for their technologies
- penetrate new markets
For additional information about how we
can assist your company, please see "About
Haberman Associates". Or use our site
map to navigate our entire site.
For an initial discussion of your company's
needs, or if you have any questions about our firm, please
contact us.
Haberman Associates is a member
of the Biopharmaceutical Consortium,
an expert team of consultancies formed in 1997 to assist
life science companies, research groups, and emerging enterprises.
May 5, 2009: Approaches
to Reducing Phase II Attrition published
by Cambridge Healthtech Institute. See our News
Page.
February 1, 2009: "Strategies
to Overcome Blood-Brain Barrier" published in Genetic
Engineering News. See our News Page
or the PDF.
January 22, 2009: Dr. Haberman speaks
at "Executing on the Promise of RNAi",
Cambridge MA. See our News Page.
September 18, 2008: Obesity Drug
Pipeline: Developing Therapies for a Complex Disease published
by Cambridge Healthtech Institute. See our News
Page.
Our online articles:
"Strategies
to Overcome Blood-Brain Barrier"
(Published in the February 1, 2009 issue of Genetic Engineering
News.)
"Addressing
Unmet Type 2 Diabetes Needs"
(Published in the January 1, 2008 issue of Genetic Engineering
News.)
"Recent
Clinical Developments in Type 2 Diabetes: Preventing Diabetes
and Preventing Cardiovascular Events in Diabetics"
(Published in the October 19, 2006 issue of CHI's Pharma
DD.)
"Safety
Issues Hamper Dual PPAR Agonists: Is Partial Antagonism
the Solution?"
(Published in the September 22, 2006 issue of CHI's Pharma
DD.)
"Breaking
the Obesity Barrier: Near-Term Prospects for Breakthrough
Treatments"
(Published in the December 22, 2005 issue of CHI's PharmaWeek.)
"Strategies
to Move Beyond Target Validation: Targets and Druggability
for Small
and Large Molecule Drugs"
(Published in the December 1, 2005 issue of Genetic Engineering
News.)
"Therapeutic
Strategies in Animal Models: the Case of Alzheimer's Disease."
(Published in the September 15, 2004 issue of Genetic
Engineering News.)
